⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5728555 | 1.00 | — | — | |
| SCHEMBL160128 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL1065086 | 0.98 | CHRM1 (0.48) | — | |
| Hydrochloric Acid SCHEMBL3819631 | 0.98 | CHRM1 (0.48) | — | |
| Urea SCHEMBL27976706 | 0.93 | CHRM1 (0.44) | — | |
| SCHEMBL288045 | 0.86 | CA2 (0.50) | — | |
| SCHEMBL429475 | 0.86 | CA2 (0.50) | — | |
| SCHEMBL201058 | 0.86 | CA2 (0.50) | — | |
| SCHEMBL27592193 | 0.85 | CHRM1 (0.41) | — | |
| SCHEMBL27984341 | 0.84 | LCK (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | claimed |
| CN-117858700-A | Controlled release local injection composition containing cyclic peptide and preparation method thereof | 东方生物股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | claimed |
| CN-116601297-A | Modified helicase and application thereof | 北京齐碳科技有限公司 | 2023-08-15 | — | — | CN | claimed |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-04-13 | — | — | US | claimed |
| US-20220372022-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-11-24 | — | — | US | claimed |
| CN-110343056-A | A kind of preparation method of N- tertbutyloxycarbonyl-N- methyl-2-amino -4,4- dimethyl valeric acid | 爱斯特（成都）生物制药股份有限公司 | 2019-10-18 | — | — | CN | claimed |
| EP-3222720-A1 | METHODS FOR PREPARING HIGH THROUGHPUT PEPTIDOMIMETICS, ORALLY BIOAVAILABLE DRUGS AND COMPOSITIONS CONTAINING SAME | University of Southern California (US) | 2017-09-27 | — | — | EP | claimed |
| CN-105636975-A | Anti-inflammatory tripeptides | DR AUGUST WOLFF GMBH & CO KG ARZNEIMITTEL | 2016-06-01 | — | — | CN | claimed |
| US-20150166606-A1 | PEPTIDE AND PEPTIDOMIMETIC INHIBITORS | RA PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | claimed |
| EP-1718602-A4 | THERAPEUTIC AND CARRIER MOLECULES | PEPLIN BIOLIPIDS PTY LTD (AU) | 2007-12-12 | — | — | EP | claimed |
| EP-1718602-A1 | THERAPEUTIC AND CARRIER MOLECULES | Peplin Biolipids Pty Ltd. (AU) | 2006-11-08 | — | — | EP | claimed |
| WO-2005073164-A1 | THERAPEUTIC AND CARRIER MOLECULES | PEPLIN BIOLIPIDS PTY LTD (AU) | 2005-08-11 | — | — | WO | claimed |
| EP-1506221-A2 | FAP-ACTIVATED ANTI-TUMOR PRODRUGS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-02-16 | — | — | EP | claimed |
| EP-1472277-A1 | FAP-ACTIVATED ANTI-TUMOR COMPOUNDS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-11-03 | — | — | EP | claimed |
| US-20040033957-A1 | FAP-activated anti-tumor prodrugs | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-02-19 | — | — | US | claimed |
| WO-2003094972-A2 | FAP-ACTIVATED ANTI-TUMOR PRODRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2003-11-20 | — | — | WO | claimed |
| US-20030211979-A1 | FAP-activated anti-tumor compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-13 | — | — | US | claimed |
| WO-2003064454-A1 | FAP-ACTIVATED ANTI-TUMOR COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2003-08-07 | — | — | WO | claimed |
| EP-1333033-A1 | FAP-activated anti-tumor compounds | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-08-06 | — | — | EP | claimed |